Side-by-side comparison of AI visibility scores, market position, and capabilities
Casual clog brand with $4B revenue including HeyDude; Gen Z cultural resurgence through celebrity collaborations and Jibbitz charm customization competing with Birkenstock for casual footwear.
Crocs is a casual footwear brand known for its distinctive foam clog shoes featuring Jibbitz charms — colorful, comfortable, and polarizing footwear that has achieved remarkable cultural staying power and consistent revenue growth despite (or because of) its unconventional aesthetic. Listed on NASDAQ (NASDAQ: CROX) and headquartered in Broomfield, Colorado, Crocs generates approximately $4 billion in annual revenue including revenue from HeyDude (a casual shoe brand acquired in 2022 for $2.5 billion) and has demonstrated consistent growth through digital marketing, celebrity collaborations, and Gen Z cultural adoption.\n\nCrocs' core product is the Classic Clog — a molded foam shoe with ventilation holes, available in 100+ colors and compatible with Jibbitz charms (small decorations that fit into the holes). The brand has expanded into sandals, platform clogs, sneakers, and boots while maintaining its distinctive material (Croslite foam). High-profile collaborations with Post Malone, Bad Bunny, Justin Bieber, Balenciaga, and luxury designers have created cult limited editions that generate enormous demand and resale market activity.\n\nIn 2025, Crocs has successfully repositioned from an awkward niche into a mainstream fashion item through social media virality and celebrity partnerships — particularly among Gen Z who appreciate its ironic fashion sensibility. The brand competes with Birkenstock, Vans, and casual footwear brands for comfortable casual shoe market share. HeyDude (a slip-on casual shoe brand) provides a more mainstream casual option within the Crocs portfolio. The 2025 strategy focuses on growing HeyDude brand awareness (the 2022 acquisition at $2.5 billion remains a work in progress), expanding Crocs internationally in Asia and Europe where brand awareness is lower than in the US, and continuing the celebrity collaboration pipeline.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.